标题
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
作者
关键词
-
出版物
CLINICAL PHARMACOKINETICS
Volume 51, Issue 8, Pages 501-514
出版商
Springer Nature
发表日期
2012-12-30
DOI
10.1007/bf03261927
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity?
- (2014) JM Lestner et al. BRITISH JOURNAL OF HOSPITAL MEDICINE
- 257 Acute Interstitial Nephritis Associated with Sitagliptin Use
- (2011) Mohammad Quasem et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Selective inhibition of dipeptidyl peptidase 4 by targeting a substrate-specific secondary binding site
- (2011) Kerstin Kühn-Wache et al. BIOLOGICAL CHEMISTRY
- Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects
- (2011) Vijay V. Upreti et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Comparative Efficacy of Vildagliptin and Sitagliptin in Japanese Patients with Type 2 Diabetes Mellitus
- (2011) James E. Signorovitch et al. CLINICAL DRUG INVESTIGATION
- Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects
- (2011) David W. Boulton et al. CLINICAL DRUG INVESTIGATION
- Effect of Multiple Oral Doses of Linagliptin on the Steady-State Pharmacokinetics of a Combination Oral Contraceptive in Healthy Female Adults
- (2011) Christian Friedrich et al. CLINICAL DRUG INVESTIGATION
- Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
- (2011) David W. Boulton et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients
- (2011) Yoshiharu Horie et al. CLINICAL THERAPEUTICS
- Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
- (2011) J. Shirakawa et al. DIABETES
- Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
- (2011) A. J. Garber DIABETES CARE
- Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
- (2011) J. J. Holst et al. DIABETES CARE
- The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus
- (2011) T. Forst et al. DIABETES OBESITY & METABOLISM
- Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*
- (2011) U. Graefe-Mody et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and HbA1c target of
- (2011) K. Esposito et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence
- (2011) R. E. van Genugten et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
- (2011) V. Lukashevich et al. DIABETES OBESITY & METABOLISM
- Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials
- (2011) Matteo Monami et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction
- (2011) R. Bhome et al. DIABETIC MEDICINE
- Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial
- (2011) J. E. Foley et al. DIABETOLOGIA
- High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV
- (2011) C. Marchetti et al. DIABETOLOGIA
- Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
- (2011) Roberta Baetta et al. DRUGS
- The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis
- (2011) Midori Ito et al. ENDOCRINE JOURNAL
- Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice
- (2011) Aurélie Waget et al. ENDOCRINOLOGY
- Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers
- (2011) C. Friedrich et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats
- (2011) Brian Chen et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes
- (2011) Y.-L. He et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers
- (2011) E.U. Graefe-Mody et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects
- (2011) A. Karim et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study
- (2011) M. Nowicki et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effect of Enhanced Glycemic Control with Saxagliptin on Endothelial Nitric Oxide Release and CD40 Levels in Obese Rats
- (2011) R. Preston Mason et al. Journal of Atherosclerosis and Thrombosis
- Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes
- (2011) Jonatan I. Bagger et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- PDB70 EVALUATION OF SITAGLIPTIN DOSING AMONG RENAL IMPAIRED TYPE 2 DIABETES MELLITUS PATIENTS
- (2011) G Krishnarajah et al. VALUE IN HEALTH
- Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice
- (2010) A. D. Dobrian et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes
- (2010) Yan-Ling He et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males
- (2010) Gary A. Herman et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects
- (2010) Silke Retlich et al. CLINICAL PHARMACOKINETICS
- Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1
- (2010) E M Migoya et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects
- (2010) Akiko Sarashina et al. CLINICAL THERAPEUTICS
- The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
- (2010) K. J. Hare et al. DIABETES
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
- (2010) S. Kasichayanula et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice
- (2010) X. Zhang et al. DIABETES OBESITY & METABOLISM
- DPP-4 inhibitors: What may be the clinical differentiators?
- (2010) John Gerich DIABETES RESEARCH AND CLINICAL PRACTICE
- Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study
- (2010) M.A. Banerji et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Exhibits Time- and Dose-Dependent Localization in Kidney, Liver, and Intestine after Intravenous Dosing: Results from High Resolution Autoradiography in Rats
- (2010) A. Greischel et al. DRUG METABOLISM AND DISPOSITION
- The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
- (2010) S. Blech et al. DRUG METABOLISM AND DISPOSITION
- Assessment of the Pharmacokinetic Interaction between the Novel DPP-4 Inhibitor Linagliptin and a Sulfonylurea, Glyburide, in Healthy Subjects
- (2010) Ulrike Graefe-Mody et al. Drug Metabolism and Pharmacokinetics
- Alogliptin
- (2010) Lesley J. Scott DRUGS
- The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats
- (2010) Alokesh Duttaroy et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Combination Therapy with Nateglinide and Vildagliptin Improves Postprandial Metabolic Derangements in Zucker Fatty Rats
- (2010) K. Miura et al. HORMONE AND METABOLIC RESEARCH
- Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
- (2010) T. Seck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effect of a High-Fat Meal on the Pharmacokinetics of Saxagliptin in Healthy Subjects
- (2010) Chirag G. Patel et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of Target-Mediated Drug Disposition on Linagliptin Pharmacokinetics and DPP-4 Inhibition in Type 2 Diabetic Patients
- (2010) Silke Retlich et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes
- (2010) Walid K.H. Fakhoury et al. PHARMACOLOGY
- Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
- (2009) Carolyn F. Deacon et al. ADVANCES IN THERAPY
- Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) - investigations in DPP-4 deficient and wildtype rats
- (2009) Silke Retlich et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats
- (2009) Holger Fuchs et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
- (2009) Mark Kirby et al. CLINICAL SCIENCE
- Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes
- (2009) Rajesh Gupta et al. CURRENT DRUG TARGETS
- Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
- (2009) T. Heise et al. DIABETES OBESITY & METABOLISM
- Saxagliptin
- (2009) Sohita Dhillon et al. DRUGS
- Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials
- (2009) Matteo Monami et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
- (2009) Richard E Pratley EXPERT OPINION ON PHARMACOTHERAPY
- Multiple Doses of Sitagliptin, a Selective DPP-4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin
- (2009) D. Hamish Wright et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of Sitagliptin on the Pharmacokinetics of Simvastatin
- (2009) Arthur J. Bergman et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants
- (2009) Aziz Karim et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Rhabdomyolysis Caused by a Potential Sitagliptin-Lovastatin Interaction
- (2009) Robert V DiGregorio et al. PHARMACOTHERAPY
- Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes
- (2009) Ronald Christopher et al. Expert Review of Clinical Pharmacology
- DPP4 inhibitors for diabetes—What next?
- (2008) Anne-Marie Lambeir et al. BIOCHEMICAL PHARMACOLOGY
- Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects
- (2008) Goutam C. Mistry et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
- (2008) R CHRISTOPHER et al. CLINICAL THERAPEUTICS
- Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
- (2008) P COVINGTON et al. CLINICAL THERAPEUTICS
- Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use
- (2008) D. P. Kao et al. DIABETIC MEDICINE
- Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
- (2008) H. He et al. DRUG METABOLISM AND DISPOSITION
- (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors
- (2008) L. Thomas et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects
- (2007) Yan-Ling He et al. JOURNAL OF CLINICAL PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started